scCURE identifies cell types responding to immunotherapy and enables outcome prediction

Xin Zou, Yujun Liu, Miaochen Wang, Jiawei Zou, Yi Shi, Xianbin Su, Juan Xu, Henry H.Y. Tong, Yuan Ji, Lv Gui, Jie Hao

Research output: Contribution to journalArticlepeer-review


A deep understanding of immunotherapy response/resistance mechanisms and a highly reliable therapy response prediction are vital for cancer treatment. Here, we developed scCURE (single-cell RNA sequencing [scRNA-seq] data-based Changed and Unchanged cell Recognition during immunotherapy). Based on Gaussian mixture modeling, Kullback-Leibler (KL) divergence, and mutual nearest-neighbors criteria, scCURE can faithfully discriminate between cells affected or unaffected by immunotherapy intervention. By conducting scCURE analyses in melanoma and breast cancer immunotherapy scRNA-seq data, we found that the baseline profiles of specific CD8+ T and macrophage cells (identified by scCURE) can determine the way in which tumor microenvironment immune cells respond to immunotherapy, e.g., antitumor immunity activation or de-activation; therefore, these cells could be predictive factors for treatment response. In this work, we demonstrated that the immunotherapy-associated cell-cell heterogeneities revealed by scCURE can be utilized to integrate the therapy response mechanism study and prediction model construction.

Original languageEnglish
Article number100643
JournalCell Reports Methods
Issue number11
Publication statusPublished - 20 Nov 2023


  • CP: Systems biology
  • cancer
  • immunotherapy
  • single-cell RNA-seq
  • therapy response prediction models


Dive into the research topics of 'scCURE identifies cell types responding to immunotherapy and enables outcome prediction'. Together they form a unique fingerprint.

Cite this